The company's stock ended at Rs 168.60, up 3.31 per cent on the BSE. During the day, it gained 7.26 per cent to Rs 175.05.
On the volume front, 2.76 lakh shares of the company changed hands at the BSE in intra-day trade.
"Claris Lifesciences has announced that it has received a report from USFDA for the inspection it conducted classifying the finished dosage plant and the API plant as acceptable," the pharma company had said in a BSE filing yesterday.
The company manufactures and markets products across various therapeutic segments including anesthesia, blood products, anti-infective and renal care.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
